Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
Top Cited Papers
Open Access
- 14 October 2012
- Vol. 2 (5), e001007
- https://doi.org/10.1136/bmjopen-2012-001007
Abstract
Despite the number of medications for type 2 diabetes, many people with the condition do not achieve good glycaemic control. Some existing glucose-lowering agents have adverse effects such as weight gain or hypoglycaemia. Type 2 diabetes tends to be a progressive disease, and most patients require treatment with combinations of glucose-lowering agents. The sodium glucose co-transporter 2 (SGLT2) receptor inhibitors are a new class of glucose-lowering agents. To assess the clinical effectiveness and safety of the SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. MEDLINE, Embase, Cochrane Library (all sections); Science Citation Index; trial registries; conference abstracts; drug regulatory authorities; bibliographies of retrieved papers. Randomised controlled trials of SGLT2 receptor inhibitors compared with placebo or active comparator in type 2 diabetes in dual or combination therapy. Systematic review. Quality assessment used the Cochrane risk of bias score. Seven trials, published in full, assessed dapagliflozin and one assessed canagliflozin. Trial quality appeared good. Dapagliflozin 10 mg reduced HbA1c by −0.54% (weighted mean differences (WMD), 95% CI −0.67 to −0.40) compared to placebo, but there was no difference compared to glipizide. Canagliflozin reduced HbA1c slightly more than sitagliptin (up to −0.21% vs sitagliptin). Both dapagliflozin and canagliflozin led to weight loss (dapagliflozin WMD −1.81 kg (95% CI −2.04 to −1.57), canagliflozin up to −2.3 kg compared to placebo). Long-term trial extensions suggested that effects were maintained over time. Data on canagliflozin are currently available from only one paper. Costs of the drugs are not known so cost-effectiveness cannot be assessed. More data on safety are needed, with the Food and Drug Administration having concerns about breast and bladder cancers. Dapagliflozin appears effective in reducing HbA1c and weight in type 2 diabetes, although more safety data are needed.Keywords
This publication has 17 references indexed in Scilit:
- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of InsulinAnnals of Internal Medicine, 2012
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trialDiabetes, Obesity and Metabolism, 2011
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With MetforminDiabetes Care, 2011
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluationHealth Technology Assessment, 2010
- Dapagliflozin, an SGLT2 inhibitor, for diabetesThe Lancet, 2010
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy SubjectsClinical Pharmacology & Therapeutics, 2009
- Molecular Analysis of the SGLT2 Gene in Patients with Renal GlucosuriaJournal of the American Society of Nephrology, 2003
- Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001JAMA, 2003
- Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO ConsultationDiabetic Medicine, 1998
- The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: Contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosisJournal of the American College of Cardiology, 1989